Oxygen Ozone Therapy in the Treatment of Chronic Obstructive Pulmonary Disease: An Integrative Approach
American Journal of Clinical and Experimental Medicine
Volume 2, Issue 2, March 2014, Pages: 9-13
Received: Jan. 19, 2014; Published: Mar. 10, 2014
Views 4285      Downloads 341
Authors
Emma Borrelli, Department of Medical Biotechnologies, University of Siena, Italy
Velio Bocci, Department of Biotechnologies, University of Siena, Italy
Article Tools
PDF
Follow on us
Abstract
A pilot study has been performed on fifty COPD patients: besides using effective drugs, half of the patients have been treated also with major ozonated autohaemotherapy . This treatment has been evaluated during the last two decades and is absolutely atoxic: the treated patients have shown a significant improvement of the six minute walking test and Saint George Respiratory Questionnaire total score. Surprisingly their quality of life was also much improved. Orthodox medications appears to be greatly potentiated when integrated by the autologous infusion of ozonated blood. This combination deserves to be evaluated in an ample clinical trial.
Keywords
Ozonetherapy, Chronic Obstructive Pulmonary Disease, Oxygen Radicals
To cite this article
Emma Borrelli, Velio Bocci, Oxygen Ozone Therapy in the Treatment of Chronic Obstructive Pulmonary Disease: An Integrative Approach, American Journal of Clinical and Experimental Medicine. Vol. 2, No. 2, 2014, pp. 9-13. doi: 10.11648/j.ajcem.20140202.11
References
[1]
Global Initiative for Obstructive Lung Disease. http://www.goldcopd.com. Last Access Sep 21, 2012
[2]
Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379: 1341–51.
[3]
Mannino DM,Buist AS.Global burden of COPD: risk factors,prevalence and future trends. Lancet 2007;370:765-73.
[4]
Hogg Jc, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009;4:435-59.
[5]
Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Resp J 2009;33: 1165-85.
[6]
Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a results of "overspill" of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010;65:930-936.
[7]
Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Resp J 2004;22:672-688
[8]
Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013 12 ; 309 (22) : 2353-61
[9]
Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Medic Res Rev 29: 646-82, 2009
[10]
Bocci V. A new method for the activation of the cellular antioxidant system. Oxidants and Antioxidants in Medical Science 2013 2 (3) 149-154.
[11]
Bocci V. Ozone. A new medical drug. 2nd Edition. Springer Editor. 2011, pp. 1-315
[12]
Borrelli E, Bocci V. Basic biological and therapeutic effects of ozonetherapy in medicine In: Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford ,UK, [http://www.eolss.net].
[13]
Bocci V. Is it true that ozone is always toxic? The end of the dogma. Toxicol. Appl. Pharmacol. 2006; 216: 493-504.
[14]
Bocci V, Zanardi I, Michaeli D, Travagli V. Mechanisms of action and chemical-biological interactions between ozone and body compartments: a critical appraisal of the different administration routes. Current Drug Therapy 2009, 4: 159-175.
[15]
Pecorelli A, Bocci V, Acquaviva A, Belmonte G, Gardi C, Virgili F, Ciccoli L, Valacchi G. Nrf2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells. Toxicology and Applied Pharmacology 2013; 267:30-40
[16]
Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society . Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society,and European Respiratory Society. Ann Intern Med 2011; 155: 179–91
[17]
Wegner R, Jörres RA, Kirsten DK, Magnussen H. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur Respir J 1994;7:725-9
[18]
O’Donnel DE.Hyperinflation, dyspnea and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 180-84.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186